Topical IL-1-Ra for Treatment of Corneal Neovascularization

Status Terminated

Clinical Trial Summary

The purpose of this study is to determine the effectiveness and safety of Interleukin-1-Receptor Antagonist eye drops for the treatment of corneal blood vessels.

Clinical Trial Description

Normally avascular, under many pathologic conditions, vessels may invade the cornea from the limbal vascular plexus. Infection, inflammation, ischemia, degeneration, or trauma, and the loss of the limbal stem cell barrier can cause corneal neovascularization. Growth of new vessels may result in corneal scarring, edema, lipid deposition, and inflammation that may alter visual acuity and is a leading cause of monocular visual impairment and blindness. Additionally, it results in the loss of immune response across the cornea, thereby worsening the prognosis of a subsequent penetrating keratoplasty (PK). Growth of new blood and lymphatic vessels from preexisting vessels are mediated by members of the vascular endothelial growth factor (VEGF) family. This study is designed to investigate whether Interleukin-1-Receptor Antagonist is a drug that is both safe and effective in blocking VEGF pathways, stopping new growth, and reducing old vessel growth. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00915590
Study type	Interventional
Source	Massachusetts Eye and Ear Infirmary
Contact
Status	Terminated
Phase	Phase 1/Phase 2
Start date	April 2009
Completion date	March 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00555594` - Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization	Phase 2/Phase 3
Completed	`NCT00004430` - Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization	N/A
Completed	`NCT00769145` - Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery	Phase 1
Completed	`NCT01257750` - Treatment of Corneal Neovascularization With Topical Pazopanib	Phase 1/Phase 2
Recruiting	`NCT04787471` - Corneal Crosslinking for Treatment of Corneal Neovascularization	Phase 2/Phase 3
Not yet recruiting	`NCT06412718` - Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
Active, not recruiting	`NCT00992849` - Bevacizumab for the Treatment of Corneal Neovascularization	Phase 2
Withdrawn	`NCT00515684` - Corneal Thinning During Topical Bevacizumab Therapy	N/A
Terminated	`NCT02797704` - Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization	Phase 1/Phase 2
Terminated	`NCT01868360` - Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea	Phase 1
Withdrawn	`NCT02042027` - Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions	Phase 1
Recruiting	`NCT04215393` - An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization	Phase 1
Completed	`NCT00797303` - The Effect of Bevacizumab on Corneal Neovascularization	Phase 4
Recruiting	`NCT05659940` - Correlation Between a Novel Subset of Neutrophil and Corneal Neovascularization.
Completed	`NCT00559936` - Topical Avastin for Treatment of Corneal Neovascularization	Phase 1
Completed	`NCT01072357` - Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival	Phase 1/Phase 2
Recruiting	`NCT04620109` - Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment	Phase 1
Completed	`NCT00512876` - Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization	N/A
Recruiting	`NCT05011916` - The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization	Phase 1/Phase 2
Completed	`NCT01996826` - A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival	Phase 1/Phase 2